At a glance
- Originator Merck & Co
- Class Antineoplastics
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 07 Jun 2001 No-Development-Reported for Cancer in USA (Unknown route)
- 03 Nov 1998 Profile reviewed
- 19 Dec 1994 Preclinical development for Cancer in USA (Unknown route)